In the case of CRC, high expression of JAK1 is associated with reduced post-progression patient survival (Hazards Ratio, HR (high) 4.28 (1.02–17.99); log rank p = 0.03) when compared with low JAK1 expressing patients (Figure 1C). This evidence concerns the gene JAK1 and colorectal carcinoma.